Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Operating Leases: 2022-2024

Historic Operating Leases for Caribou Biosciences (CRBU) over the last 3 years, with Dec 2024 value amounting to $25.1 million.

  • Caribou Biosciences' Operating Leases fell 14.50% to $22.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.8 million, marking a year-over-year decrease of 14.50%. This contributed to the annual value of $25.1 million for FY2024, which is 3.27% down from last year.
  • Caribou Biosciences' Operating Leases amounted to $25.1 million in FY2024, which was down 3.27% from $25.9 million recorded in FY2023.
  • Caribou Biosciences' Operating Leases' 5-year high stood at $26.8 million during FY2022, with a 5-year trough of $25.1 million in FY2024.
  • Moreover, its 3-year median value for Operating Leases was $25.9 million (2023), whereas its average is $25.9 million.
  • Data for Caribou Biosciences' Operating Leases shows a maximum YoY fell of 3.27% (in 2024) over the last 5 years.
  • Caribou Biosciences' Operating Leases (Yearly) stood at $26.8 million in 2022, then fell by 3.26% to $25.9 million in 2023, then fell by 3.27% to $25.1 million in 2024.